Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life-threatening acute respiratory and critical care conditions, including respiratory depression caused by drug overdose, post-surgery, and other conditions. The Company is planning to initiate pivotal studies for its lead compound ENA-001 in the near term.

Pharmaceutical

Enalare Therapeutics

Herm Cukier

Mark Coleman

Timothy P. McGurrin

Robert Raffa

Marty Lutz

Joseph Pergolizzi

Frank Diana

Thomas Miller

Daniel Motto

The Leadership Team at Enalare Therapeutics drives the strategic direction and operational execution of the company. This team, comprised of executives from regulatory affairs, clinical development, and operations, collaborates to guide the development and commercialization of innovative therapies for acute respiratory conditions, ensuring compliance with regulatory standards and effective clinical trial implementation to advance their lead compound, ENA-001, towards pivotal studies.

Leadership Team

Advisory Board

Clinical Development and Regulatory Affairs

Leadership Team

About

Team members

Other teams at Enalare Therapeutics

Advisory Board

Clinical Development and Regulatory Affairs